Published in Biotech Business Week, October 25th, 2004
"The U.S. government's decision to further develop and acquire Imvamune recognizes the advanced stage of our clinical research program and the need for a safe vaccine for the American public," said Peter Wulff, CEO, Bavarian Nordic.
"Ultimately, it is essential that the United States stockpiles a single, safe and effective smallpox vaccine...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Biotech Business Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.